



Fidelity Global Health Care Class of the Fidelity Capital Structure Corp.

**Annual Management
Report of Fund
Performance**
November 30, 2024

Caution Regarding Forward-looking Statements

Certain portions of this report, including, but not limited to, “Results of Operations” and “Recent Developments”, may contain forward-looking statements about the Fund, including its strategy, risks, expected performance and condition. Forward-looking statements include statements that are predictive in nature, that depend upon or refer to future events or conditions, or that include words such as “expects”, “anticipates”, “intends”, “plans”, “believes”, “estimates” and similar forward-looking expressions or negative versions thereof.

In addition, any statement that may be made concerning future performance, strategies or prospects, and possible future Fund action, is also a forward-looking statement. Forward-looking statements are based on current expectations and projections about future events and are inherently subject to, among other things, risks, uncertainties and assumptions about the Fund and economic factors. Accordingly, assumptions concerning future economic and other factors may prove to be incorrect at a future date.

Forward-looking statements are not guarantees of future performance, and actual events and results could differ materially from those expressed or implied in any forward-looking statements made by the Fund. Any number of important factors could contribute to these digressions, including, but not limited to, general economic, political and market factors in North America and internationally, interest and foreign exchange rates, global equity and capital markets, business competition, technological change, changes in government regulations, unexpected judicial or regulatory proceedings, and catastrophic events.

It should be stressed that the above-mentioned list of important factors is not exhaustive. You are encouraged to consider these and other factors carefully before making any investment decisions and you are urged to avoid placing undue reliance on forward-looking statements. Further, you should be aware of the fact that the Fund has no specific intention of updating any forward-looking statements whether as a result of new information, future events or otherwise, prior to the release of the next Management Report of Fund Performance.

Annual Management Report of Fund Performance as at November 30, 2024

Fidelity Global Health Care Class of the Fidelity Capital Structure Corp.

This annual management report of fund performance contains financial highlights but does not contain the complete annual financial statements for the investment fund. You can get a copy of the annual financial statements at your request, and at no cost, by calling 1-800-263-4077, by writing to us at Fidelity Investments, 483 Bay St. Suite 300, Toronto ON M5G 2N7 or by visiting our website at www.fidelity.ca or SEDAR+ at www.sedarplus.ca.

Securityholders may also contact us using one of these methods to request a copy of the investment fund's proxy voting policies and procedures, proxy voting disclosure record or quarterly portfolio disclosure relating to the investment fund.

Management Discussion of Fund Performance

Investment Objective and Strategies

Investment Objective: Fidelity Global Health Care Class (Fund) aims to achieve long-term capital growth. It seeks a return similar to that of Fidelity Global Health Care Fund (Underlying Fund), by investing substantially all of its assets in securities of the Underlying Fund. The Underlying Fund aims to achieve long-term capital growth by investing in equity securities of companies anywhere in the world that design, make or sell products or services related to health care and medicine.

Strategies: The portfolio manager invests in companies in the health care industry, including biotechnology firms, and health management organizations and companies involved in hospital management, medical products, and pharmaceuticals. When buying and selling securities for the Underlying Fund, the portfolio manager examines each company's potential for success in light of its current financial condition, industry position, growth potential, earning estimates, quality of management, as well as economic and market conditions. The Underlying Fund may invest in small-, medium- and large-capitalization companies. It may hold cash and invest in fixed-income securities.

Risk

The risks associated with investing in this Fund remain as discussed in the prospectus. Any changes to the Fund over the period have not affected the overall level of risk of the Fund.

The Fund is suitable for long-term investors who want to gain exposure to health care companies anywhere in the world, and can handle the volatility of returns generally associated with equity investments. Registered plan investors should be aware that the Fund may, from time to time, bear an income tax expense which will reduce returns. To invest in the Fund, investors should be willing to accept a medium level of risk. The suitability of the investment has not changed from what has been disclosed in the prospectus.

Results of Operations

Fidelity Global Health Care Class, Series B, returned 13.5%, after fees and expenses, for the twelve-month period ended November 30, 2024. The net returns of the other series of the Fund are similar to those of Series B, except for differences attributable to expense structures. During the review period, global equities, as represented by the MSCI World Index, returned 32.0% (in Canadian dollar terms).

Market overview:

Global equities, as broadly measured by the MSCI World Index, returned 32.0% in Canadian dollar terms and 27.8% in U.S. dollar terms, for the one-year period ended November 30, 2024.

Global equities advanced for the period under review. Falling interest rates in major developed markets, decreasing inflation, and positive U.S. economic data, helped support investor confidence. Investor optimism in the digital innovation and artificial intelligence space helped fuel growth in the information technology and communication services sectors, propelling the technology-heavy NASDAQ Index to record highs. However, investor sentiment shifted later in the review period due to concerns about stretched valuations and relatively weaker U.S. economic growth. Valuations of companies in the financials sector rose, signalling optimism about potential earnings growth from reduced borrowing costs. Defensive sectors, such as utilities and consumer staples, also gained as investors looked for stability amidst ongoing market volatility. In Europe, equities surged despite some volatility along the way. Markets recovered as the European Central Bank implemented rate cuts, and China's central bank embarked on its most significant stimulus since the pandemic, in effort to ease the deflationary cycle. Japanese equities experienced volatility, amid shifting monetary policy expectations. The interest rate hike by the Bank of Japan led to a rapid unwinding of leveraged global trades, which created market volatility.

Factors affecting performance:

The Fund underperformed its broad-based benchmark, the MSCI World Index. The Underlying Fund's investments in, and higher-than-benchmark exposure to, the life sciences, tools and services industry detracted from relative returns. Higher-than-benchmark exposure to the health care providers and services industry also detracted from relative returns.

The Fund's benchmark, the MSCI ACWI (All Country World Index) Health Care Index, returned 16.2% (in Canadian dollar terms) for the review period. The Fund underperformed its benchmark for the review period, primarily due to the Underlying Fund's investments in the life sciences, tools and services industry, where an out-of-benchmark exposure to Ireland-based clinical research services provider ICON and an investment in U.S.-based pharmaceutical company West Pharmaceutical Services detracted from relative returns. Investments in health care providers and services industry such as U.S.-based health insurance company Elevance Health and U.S.-based home health care services company Humana, also detracted from relative returns. In other industries, the Underlying Fund's lower-than-benchmark exposure to U.S.-based pharmaceuticals company Eli Lilly & Co. and an investment in U.S.-based biotechnology company Regeneron Pharmaceuticals detracted from relative returns.

In contrast, investments in certain stocks in the health care equipment and supplies industry, such as U.S.-based medical technology companies Boston Scientific Corp. and Stryker Corp., contributed to relative returns. Certain investments in the pharmaceuticals industry also contributed to relative returns, such as Belgium-based biopharmaceutical company UCB, and a lack of exposure to a U.S.-based pharmaceutical company. In other industries, an investment in U.S.-based health care facilities provider HCA Healthcare contributed to relative returns.

At the end of the review period, the Underlying Fund had no exposure to West Pharmaceutical Services or Humana.

Portfolio changes:

The Underlying Fund's portfolio manager takes a bottom-up approach to stock selection and uses Fidelity's research capabilities to tap global investment opportunities in this sector.

Fidelity Global Health Care Class of the Fidelity Capital Structure Corp. Management Discussion of Fund Performance – continued

During the review period, the Underlying Fund increased its allocations to the health care equipment and supplies industry and the biotechnology industry. In the health care equipment and supplies industry, the portfolio manager initiated a position in Boston Scientific Corp. In the biotechnology industry, a position was initiated in U.S.-based global biotechnology company Vertex Pharmaceuticals. The portfolio manager believes these companies have attractive investment growth potential.

In contrast, exposure to the health care providers and services industry and the pharmaceuticals industry was decreased. In the health care providers and services industry, the portfolio manager exited a position in Humana in favour of what the manager believes are more attractive opportunities elsewhere with more potential. In the pharmaceuticals industry, the portfolio manager reduced exposure to Switzerland-based pharmaceutical company Roche Holding.

At the end of the review period, the Underlying Fund had its largest exposure to the health care equipment and supplies industry, followed by the pharmaceuticals industry. The Underlying Fund diverged the most from its benchmark's sector weightings by having more exposure to the health care equipment and supplies industry and less exposure to the pharmaceuticals industry.

Recent Developments

Portfolio manager Alex Gold's investment philosophy is based on three pillars: quality, visibility and sustainability. The portfolio manager's bottom-up investment approach seeks to identify health care businesses with superior and sustainable return on invested capital, high levels of free cash-flow generation, a good track record and a history of disciplined capital allocation. The portfolio manager believes the health care sector is highly attractive for investing and seeks to identify high-quality companies set to benefit from two long-term structural growth drivers in health care: an aging population and increased health care needs. To identify leaders in innovation, the manager focuses on research and development, which the portfolio manager believes are the backbone of any company's success. This focus enables the portfolio manager to identify companies that the manager believes are playing a key role in the evolution of health care, ensuring better outcomes for patients and driving down costs for the health system.

Related Party Transactions

Manager and Portfolio Adviser

The Fund is managed by Fidelity Investments Canada ULC (Fidelity). Fidelity is part of a broader collection of companies collectively known as Fidelity Investments.

Fidelity provides or arranges for the provision of all general management and administrative services required by the Fund in its day-to-day operations, bookkeeping, record-keeping and other administrative services for the Fund.

Fidelity is the portfolio adviser to the Fund and it provides investment advisory services to the Fund. Fidelity has entered into sub-advisory agreements with a number of entities including FIL Limited to provide investment advice with respect to all or a portion of the investments of the Fund. The sub-advisors arrange for acquisition and disposition of portfolio investments, including all necessary brokerage arrangements. The Fund pays Fidelity a monthly management and advisory fee for their services, based on the net asset value of each Series, calculated daily and payable monthly. The Fund paid Fidelity management and advisory fees of \$757,000 for the period ended November 30, 2024.

Administration Fee

Fidelity charges the Fund a fixed administration fee in place of certain variable expenses. Fidelity, in turn, pays all of the operating expenses of the Fund, other than certain specified fund costs (e.g. the fees and expenses of the Independent Review Committee, taxes, brokerage commissions and interest charges). The Fund pays an annual rate, which is calculated on a tiered basis, based on the net asset value of each Series, calculated daily and payable monthly. The Fund paid Fidelity administration fees of \$97,000 for the period ended November 30, 2024.

Independent Review Committee, Cross-Trading and In specie Transactions

Independent Review Committee

Fidelity has established an independent review committee (IRC) that acts as an impartial and independent committee to review and provide recommendations or, if appropriate, approvals respecting conflict of interest matters referred to it by Fidelity. The IRC prepares, at least annually, a report of its activities for securityholders of the Fund. The report is available at www.fidelity.ca or at the securityholder's request at no cost by contacting Fidelity, using the contact information available on the final page of this document.

Cross-Trading and In specie Transactions

The Fund received the approval and standing instructions from the IRC in order to:

- (i) engage in cross-trading, which is a form of interfund trading. A cross-trade occurs when the Fund purchases or sells portfolio securities from or to another Fund, a U.S. fund or a separately managed account, through a broker;
- (ii) permit the Fund, in certain circumstances, to purchase and redeem Fund securities in consideration for securities rather than cash of another investment fund not governed by NI 81-102, or a separately managed account, managed by Fidelity.

For each of the transactions in (i) and (ii) above, the IRC's standing instructions require Fidelity to act in accordance with its associated policies and procedures and applicable law, and comply with the conditions in each of the exemptive relief orders received, which, in the case of cross-trading, requires additional periodic reporting to the Ontario Securities Commission. The standing instructions also require that investment decisions in respect of these transactions (a) are free from any influence by an entity related to Fidelity and without taking into account any consideration relevant to an entity related to Fidelity; (b) represent the business judgment of Fidelity uninfluenced by considerations other than the best interests of the Fund; (c) comply with the applicable policies and procedures of Fidelity; and (d) achieve a fair and reasonable result for the Fund.

Financial Highlights

The following tables show selected key financial information about the Fund and are intended to help you understand the Fund's financial performance for the period end of the years shown. This information is derived from the Fund's audited annual and/or unaudited semi-annual financial statements. Please see the front page for information about how you can obtain the Fund's annual or semi-annual financial statements.

Fidelity Global Health Care Class of the Fidelity Capital Structure Corp. Series A

Periods ended November 30, The Series' Net Assets per Security ^A	2024	2023	2022	2021	2020
Net assets, beginning of period ^B	\$ 32.90	\$ 33.19	\$ 33.51	\$ 29.36	\$ 27.00
Increase (decrease) from operations:					
Total revenue	—	—	—	—	—
Total expenses (excluding distributions)	(.91)	(.81)	(.80)	(.81)	(.72)
Realized gains (losses)	1.93	1.43	1.29	1.17	1.23
Unrealized gains (losses)	3.80	(1.11)	(1.34)	3.87	1.76
Total increase (decrease) from operations ^B	4.82	(.49)	(.85)	4.23	2.27
Distributions:					
From net investment income (excluding dividends)	—	—	—	—	—
From dividends	—	—	—	—	—
From capital gains	—	—	—	—	—
Return of capital	—	—	—	—	—
Total distributions ^{B,C}	—	—	—	—	—
Net assets, end of period ^B	\$ 37.26	\$ 32.90	\$ 33.19	\$ 33.51	\$ 29.36
Ratios and Supplemental Data					
Net asset value (000s) ^{D,E}	\$ 2,708	\$ 3,193	\$ 4,580	\$ 6,152	\$ 5,227
Securities outstanding ^D	72,687	97,049	137,971	183,588	178,024
Management expense ratio ^{F,G}	2.49%	2.50%	2.51%	2.53%	2.55%
Management expense ratio before waivers or absorptions ^{F,G}	2.57%	2.57%	2.58%	2.60%	2.63%
Trading expense ratio ^H	.06%	.03%	.05%	.04%	.06%
Portfolio turnover rate ^I	11.26%	9.74%	23.51%	13.78%	16.66%
Net asset value per security, end of period	\$ 37.2579	\$ 32.9044	\$ 33.1921	\$ 33.5072	\$ 29.3610

Fidelity Global Health Care Class of the Fidelity Capital Structure Corp. Series B

Periods ended November 30, The Series' Net Assets per Security ^A	2024	2023	2022	2021	2020
Net assets, beginning of period ^B	\$ 34.21	\$ 34.42	\$ 34.66	\$ 30.31	\$ 27.81
Increase (decrease) from operations:					
Total revenue	—	—	—	—	—
Total expenses (excluding distributions)	(.86)	(.76)	(.74)	(.77)	(.68)
Realized gains (losses)	1.99	1.59	1.34	1.41	1.27
Unrealized gains (losses)	3.44	(1.13)	(1.02)	2.71	1.92
Total increase (decrease) from operations ^B	4.57	(.30)	(.42)	3.35	2.51
Distributions:					
From net investment income (excluding dividends)	—	—	—	—	—
From dividends	—	—	—	—	—
From capital gains	—	—	—	—	—
Return of capital	—	—	—	—	—
Total distributions ^{B,C}	—	—	—	—	—
Net assets, end of period ^B	\$ 38.83	\$ 34.21	\$ 34.42	\$ 34.66	\$ 30.31
Ratios and Supplemental Data					
Net asset value (000s) ^{D,E}	\$ 23,496	\$ 21,583	\$ 24,658	\$ 24,662	\$ 11,375
Securities outstanding ^D	605,150	630,896	716,335	711,568	375,296
Management expense ratio ^{F,G}	2.26%	2.25%	2.25%	2.31%	2.33%
Management expense ratio before waivers or absorptions ^{F,G}	2.32%	2.31%	2.32%	2.39%	2.40%
Trading expense ratio ^H	.06%	.03%	.05%	.04%	.06%
Portfolio turnover rate ^I	11.26%	9.74%	23.51%	13.78%	16.66%
Net asset value per security, end of period	\$ 38.8296	\$ 34.2109	\$ 34.4233	\$ 34.6608	\$ 30.3087

Financial Highlights – continued

Fidelity Global Health Care Class of the Fidelity Capital Structure Corp. Series F

Periods ended November 30, The Series' Net Assets per Security ^A	2024	2023	2022	2021	2020
Net assets, beginning of period ^B	\$ 43.07	\$ 43.14	\$ 42.99	\$ 37.18	\$ 33.73
Increase (decrease) from operations:					
Total revenue	—	—	—	—	—
Total expenses (excluding distributions)	(.55)	(.48)	(.47)	(.50)	(.43)
Realized gains (losses)	2.53	1.83	1.55	1.81	1.48
Unrealized gains (losses)	4.47	(1.51)	(1.43)	2.70	1.94
Total increase (decrease) from operations ^B	6.45	(.16)	(.35)	4.01	2.99
Distributions:					
From net investment income (excluding dividends)	—	—	—	—	—
From dividends	—	—	—	—	—
From capital gains	—	(.28)	(.03)	—	—
Return of capital	—	—	—	—	—
Total distributions ^{B,C}	—	(.28)	(.03)	—	—
Net assets, end of period ^B	\$ 49.44	\$ 43.07	\$ 43.14	\$ 42.99	\$ 37.18
Ratios and Supplemental Data					
Net asset value (000s) ^{D,E}	\$ 30,916	\$ 28,805	\$ 34,199	\$ 22,025	\$ 8,104
Securities outstanding ^D	625,397	668,844	792,683	512,316	217,999
Management expense ratio ^{F,G}	1.13%	1.14%	1.14%	1.20%	1.20%
Management expense ratio before waivers or absorptions ^{F,G}	1.16%	1.17%	1.17%	1.24%	1.24%
Trading expense ratio ^H	.06%	.03%	.05%	.04%	.06%
Portfolio turnover rate ^I	11.26%	9.74%	23.51%	13.78%	16.66%
Net asset value per security, end of period	\$ 49.4359	\$ 43.0685	\$ 43.1444	\$ 42.9923	\$ 37.1768

Financial Highlights Footnotes

- ^A This information is derived from the Fund's audited annual and/or unaudited interim financial statements. The net assets attributable to securityholders per security presented in the financial statements may differ from the net asset value calculated for fund pricing purposes. An explanation of these differences can be found in the notes to financial statements.
- ^B Net assets and distributions are based on the actual number of securities outstanding at the relevant time. The increase (decrease) from operations is based on the weighted average number of securities outstanding over the financial period. This table is not intended to be a reconciliation of beginning to ending net assets per security.
- ^C Distributions were paid in cash or reinvested in additional securities of the Fund, or both, and excludes any applicable distributions of management fee reduction to securityholders.
- ^D This information is provided as at period end of the year shown.
- ^E Prior period amounts may have been adjusted.
- ^F Management expense ratio is based on total expenses (excluding distributions, commissions and other portfolio transaction costs) for the stated period and is expressed as an annualized percentage of daily average net asset values during the period, including the Fund's pro-rata share of estimated expenses incurred in any underlying investment fund, if applicable.
- ^G Effective November 1, 2014, the manager of the Fund has waived a portion of its administration fee and as of the date of the MRFP has continued to provide the Fund with such waivers. The manager may terminate the waiver at any time, at its sole discretion. It is not known when such waivers will be terminated.
- ^H The trading expense ratio represents total commissions, other portfolio transaction costs and dividends and interest expense on securities sold short expressed as an annualized percentage of daily average net asset value during the period, including the Fund's pro-rata share of estimated trading costs incurred in any underlying investment fund, if applicable.
- ^I The Fund's portfolio turnover rate indicates how actively the Fund's portfolio adviser manages its portfolio investments. A portfolio turnover rate of 100% is equivalent to the Fund buying and selling all of the securities in its portfolio once in the course of the year. The higher the Fund's portfolio turnover rate in a year, the greater the trading costs payable by the Fund in the year, and the greater chance of an investor receiving taxable capital gains in the year. There is not necessarily a relationship between a high portfolio turnover rate and the performance of the Fund. The portfolio turnover rate is calculated based on the lesser of purchases or sales of securities divided by the weighted average market value of portfolio securities owned by the Fund, excluding short-term securities. The portfolio turnover rate includes any proceeds from a short sale in the value of sales of securities and the cost of covering a short sale in the value of purchases of securities. For periods greater than six months, but less than a full fiscal year, the portfolio turnover rate is annualized. The portfolio turnover rate excludes any adjustment for in-kind transactions.

Management and Advisory Fees

Fidelity serves as manager and investment advisor of the Fund. The Fund pays Fidelity a monthly management and advisory fee for its services, based on the net asset value of each Series, calculated daily and payable monthly. Fidelity uses these management fees to pay for sales and trailing commissions to registered dealers on the distribution of the Fund securities, as well as for the general investment management expenses. Dealer compensation represents cash commissions paid by Fidelity to registered dealers during the period and includes upfront deferred sales charge and trailing commissions. This amount may, in certain circumstances, exceed 100% of the fees earned by Fidelity during the period. For new Funds or Series the amounts presented may not be indicative of longer term operating periods.

	Management Fees (%)	Dealer Compensation (%)	Investment management, administration and other (%)
Series A	2.000	23.18	76.82
Series B	1.850	54.05	45.95
Series F	0.850	-	100.00




Fidelity Global Health Care Class of the Fidelity Capital Structure Corp.

Past Performance

The performance information shown assumes that all distributions made by the Fund in the periods shown were reinvested in additional securities of the Fund. The performance information does not take into account sales, redemption, distribution or other optional charges, or income taxes payable by any investor that would have reduced returns or performance. How the Fund has performed in the past does not necessarily indicate how it will perform in the future.

Year-by-Year Returns

The following bar chart shows the Fund's annual performance for each of the years shown, and illustrates how the Fund's performance was changed from year to year. In percentage terms, the bar chart shows how much an investment made on the first day of each financial year would have grown or decreased by the last day of each financial year.



Annual Compound Returns

This table shows the Fund's historical annual compound total returns for the periods indicated, compared with a broad-based benchmark, the MSCI World Index, and the Fund's benchmark, the MSCI ACWI (All Country World Index) Health Care Index, as described below.

Average Annual Total Returns	Past 1 year	Past 3 years	Past 5 years	Past 10 years
Series A	13.2%	3.6%	6.6%	8.0%
Series B	13.5%	3.9%	6.9%	8.2%
Series F	14.8%	5.0%	8.1%	9.5%
MSCI World Index	32.0%	12.0%	13.6%	12.3%
MSCI ACWI (All Country World Index) Health Care Index	16.2%	7.3%	9.5%	10.1%

A discussion of Fund performance can be found in the "Results of Operations" section of this report.

The MSCI ACWI (All Country World Index) Health Care Index is an unmanaged index considered representative of the health care sector.

The MSCI World Index is a market-capitalization-weighted index composed of companies representative of the market structure of developed market countries in North America, Europe and the Asia/Pacific region.

**Fidelity Global Health Care Class of the Fidelity Capital Structure Corp.
Past Performance – continued**

Each series of the Fund will have different returns because of differences in management fees and expenses.

Fidelity Global Health Care Class of the Fidelity Capital Structure Corp.

Summary of Investment Portfolio as at November 30, 2024

Sector Mix

	% of Fund's Net Assets as at November 30, 2024	% of Fund's Net Assets as at November 30, 2023
Health Care Equipment & Supplies	30.4	19.1
Pharmaceuticals	24.4	27.2
Health Care Providers & Services	16.1	20.2
Life Sciences Tools & Services	16.0	18.4
Biotechnology	10.2	9.0
Others (Individually Less Than 1%)	0.0	2.7
Cash and Cash Equivalents	2.6	3.6
Net Other Assets (Liabilities)	0.3	(0.2)

Comparative balances, as applicable, have been reclassified to align with current period presentation.

Geographic Mix

	% of Fund's Net Assets as at November 30, 2024	% of Fund's Net Assets as at November 30, 2023
United States of America	73.1	76.3
Denmark	8.5	6.6
United Kingdom	7.4	6.0
France	2.8	1.8
Belgium	2.1	0.0
Switzerland	1.8	4.4
Japan	1.4	0.0
Others (Individually Less Than 1%)	0.0	1.5
Cash and Cash Equivalents	2.6	3.6
Net Other Assets (Liabilities)	0.3	(0.2)

Top Issuers

	% of Fund's Net Assets
1. UnitedHealth Group, Inc.	9.5
2. Boston Scientific Corp.	7.5
3. Novo Nordisk A/S	5.8
4. Stryker Corp.	5.5
5. Eli Lilly & Co.	5.2
6. AstraZeneca PLC	4.5
7. Thermo Fisher Scientific, Inc.	4.3
8. Intuitive Surgical, Inc.	4.1
9. Danaher Corp.	3.9
10. ICON PLC	3.9
11. HCA Holdings, Inc.	2.8
12. Regeneron Pharmaceuticals, Inc.	2.8
13. Fidelity U.S. Money Market Investment Trust – Series O	2.7
14. Elevance Health, Inc.	2.7
15. Roche Holding AG	2.6
16. UCB SA	2.1
17. Vertex Pharmaceuticals, Inc.	2.1
18. AbbVie, Inc.	2.1
19. ConvaTec Group PLC	2.0
20. Amgen, Inc.	1.9
21. Insulet Corp.	1.9
22. Coloplast A/S	1.9
23. Mettler–Toledo International, Inc.	1.9
24. Sonova Holding AG	1.8
25. Sanofi SA	1.7
	<u>87.2</u>

Total Fund Net Assets \$57,120,000

Summary of Investment Portfolio as at November 30, 2024 – continued

Where applicable, the information in the above tables includes the Fund's pro-rata share of the investment in any Fidelity managed underlying fund.

All tables within the Summary of Investment Portfolio section, except the Top Issuers table, contain audited annual information.

The summary of investment portfolio may change due to ongoing portfolio transactions of the investment fund. The most recent annual report, semi-annual report, quarterly report, fund facts document or simplified prospectus for the investment fund and/or underlying fund is available at no cost, by calling 1-800-263-4077, by writing to us at Fidelity Investments Canada ULC, 483 Bay St. Suite 300, Toronto ON M5G 2N7 or by visiting our web site at www.fidelity.ca or SEDAR+ at www.sedarplus.ca.



Fidelity Capital Structure Corp.
407 2nd Street S.W., Suite 820
Calgary, Alberta T2P 2Y3

Manager and Registrar

Fidelity Investments Canada ULC
483 Bay Street, Suite 300
Toronto, Ontario M5G 2N7

Custodian

State Street Trust Company of Canada
Toronto, Ontario

Visit us online at

www.fidelity.ca

or call Fidelity Client Services
at 1-800-263-4077

Fidelity's mutual funds are sold by registered Investment Professionals. Each Fund has a simplified prospectus, which contains important information on the Fund, including its investment objective, purchase options, and applicable charges. Please obtain a copy of the prospectus, read it carefully, and consult your Investment Professional before investing. As with any investment, there are risks to investing in mutual funds. There is no assurance that any Fund will achieve its investment objective, and its net asset value, yield, and investment return will fluctuate from time to time with market conditions. Investors may experience a gain or loss when they sell their securities in any Fidelity Fund. Fidelity Global Funds may be more volatile than other Fidelity Funds as they concentrate investments in one sector and in fewer issuers; no single Fund is intended to be a complete diversified investment program. Past performance is no assurance or indicator of future returns. There is no assurance that either Fidelity Canadian Money Market Fund, Fidelity Canadian Money Market Investment Trust, Fidelity U.S. Money Market Fund or Fidelity U.S. Money Market Investment Trust will be able to maintain its net asset value at a constant amount. The breakdown of Fund investments is presented to illustrate the way in which a Fund may invest, and may not be representative of a Fund's current or future investments. A Fund's investments may change at any time.

®Fidelity Investments is a registered trademark of Fidelity Investments Canada ULC.